Diagnosing Early Lupus from Mimics

Dec 8th, 2018 - A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. The cohorts included 389 patients with early SLE and 227 patients with SLE‐mimicking conditions. The diagnosis was based on the 1997 American College of Rheumatology (ACR)...

ACR, NPF unveil new psoriatic arthritis treatment guideline
Doug Brunk

Dec 6th, 2018 - The American College of Rheumatology and the National Psoriasis Foundation have released a joint treatment guideline for psoriatic arthritis that, for the first time, includes a conditional recommendation to use tumor necrosis factor–inhibitor(TNFi) biologics over methotrexate and other oral small molecules as a first-line therapy in patients with active disease. Dr.

Large cohort study IDs prognostic factors in thromboangiitis obliterans
Sharon Worcester

Dec 5th, 2018 - CHICAGO – Nonwhite ethnicity and limb infection at diagnosis predict vascular events in patients with thromboangiitis obliterans (TAO), and the latter also predicts amputation, which occurs within 10 years of diagnosis in nearly a third of patients, according to findings from a large retrospective French cohort study. Shidlovski/gettyimages After a mean follow-up of 5.

Understanding Results From the PEXIVAS Trial

Dec 3rd, 2018 - Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) refers to a group of vasculitides that mainly affect small vessels and are pauci-immune in nature. In particular, granulomatosis with polyangiitis (GPA) is associated with significant morbidity and mortality, primarily from disease affecting the kidneys and lungs. Renal disease, in the form of rapidly progressive glomerulonephriti...

RELIEF: In Behçet’s, apremilast improves oral ulcers for up to 28 weeks
Sharon Worcester

Dec 1st, 2018 - CHICAGO – Apremilast was effective and well tolerated for up to 28 weeks for the treatment of oral ulcers in patients with active Behçet’s disease, based on findings from the randomized, placebo-controlled, phase 3 RELIEF trial. At baseline, mean oral ulcer counts were 4.

DMARDs improve vascular abnormalities in early RA
Bruce Jancin, MDedge News

Nov 30th, 2018 - CHICAGO – Patients with newly diagnosed RA have subclinical abnormalities in vascular function that are favorably altered after they start to take disease-modifying anti-rheumatic drugs, Maya H. Buch, PhD, said at the annual meeting of the American College of Rheumatology.

Weight loss cuts risk of psoriatic arthritis
Bruce Jancin

Nov 29th, 2018 - CHICAGO – Overweight and obese psoriasis patients have it within their power to reduce their risk of developing psoriatic arthritis through weight loss, according to a large British longitudinal study. Bruce Jancin/MDedge News Dr.

Intra-articular Wnt inhibitor for knee OA sails through phase 2
Bruce Jancin

Nov 29th, 2018 - CHICAGO – A single intra-articular injection of a novel drug known for now as SMO4690 resulted in statistically significant and clinically meaningful improvements in pain and physical function through 6 months of follow-up in a phase 2b study including 695 patients with moderately to severely symptomatic knee OA, Yusuf Yazici, MD, reported at the annual meeting of the American College of Rheuma.

Knowledge, attitudes about prescription NSAID use for OA varies by ethnicity

Nov 29th, 2018 - Hispanic patients with osteoarthritis were less likely than non-Hispanic white patients to believe that prescription NSAIDs could help or harm them, according to research presented at the ACR/ARHP 2018 Annual Meeting.

Post-Traumatic Osteoarthritis: Managing OA That Develops After Joint Injuries & Reconstructive Surgery
Bernstein, S.

Nov 28th, 2018 - Joint trauma is one of many potential drivers of osteoarthritis disease activity and structural progression. In Post-Traumatic OA: Pathogenesis, Clinical Evolution and Management, a session at the 2018 ACR/ARHP Annual Meeting, experts discussed the effects of sports and other injuries on even young patients’ joints.

Nonsurgical Therapies for Knee OA Pain: From Medications to Bracing to Exercise, What Works & What Doesn’t
Bernstein, S.

Nov 28th, 2018 - Many nonsurgical therapies are available for knee osteoarthritis pain, but they vary greatly in effectiveness.

Emerging Treatments for OA: New Therapies Target Joint Pain, Not Just Structural Damage
Bernstein, S.

Nov 28th, 2018 - Are effective treatments for osteoarthritis (OA) on the horizon? In Emerging Treatments for Osteoarthritis at the 2018 ACR/ARHP Annual Meeting, experts discussed potential therapies to address OA structural progression, pain and inflammation.

Glucocorticoid elimination works for 2/3 of RA patients on tocilizumab
Mitchel L. Zoler

Nov 27th, 2018 - CHICAGO – Nearly two-thirds of rheumatoid arthritis patients who achieved remission or low disease activity on tocilizumab plus low-dose prednisone were able to taper off prednisone treatment while remaining in at least low disease activity in a multicenter, randomized trial with 259 patients. Mitchel L.

FDA urged to bring rheumatologists into gadolinium safety discussion
Bruce Jancin

Nov 27th, 2018 - CHICAGO – The Food and Drug Administration’s updated safety warning about gadolinium-based contrast agents was dismissed as too little, too late during a postsession discussion at the annual meeting of the American College of Rheumatology. Bruce Jancin/MDedge News Dr.

Bimekizumab improves outcomes among PsA patients

Nov 27th, 2018 - Bimekizumab, a monoclonal antibody that neutralizes both IL-17A and IL-17F, significantly improved both musculoskeletal and skin outcomes among patients with active psoriatic arthritis, according to phase 2b data presented at the ACR/ARHP 2018 Annual Meeting.

Nerve growth factor antibody cuts OA pain with low AEs
Mitchel L. Zoler

Nov 26th, 2018 - CHICAGO – The nerve growth factor antibody tanezumab met its primary efficacy endpoints for improving pain and physical function in patients with knee or hip OA while also showing a low incidence of the drug’s most concerning adverse effect in the first results from a phase 3 study of a drug in this new class. Mitchel L.

Montreal Cognitive Assessment fares well for rapid, reliable screening in SLE
Bruce Jancin

Nov 26th, 2018 - CHICAGO – The Montreal Cognitive Assessment Test provides persuasive advantages over the standard neuropsychological test battery often recommended in guidelines as a screening tool for cognitive impairment in patients with systemic lupus erythematosus, Nicolas Paez-Venegas, MD, asserted at the annual meeting of the American College of Rheumatology. Related VIDEO: Assessment tool rapidly screen.